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Abstract
Background: Two formulations of Pegylated interferon (Peg-IFN) are on the market for treatment of chronic
hepatitis C virus (HCV) infection. The purpose of this meta-analysis was to assess the efficacy of Peg-IFN α-2a versus
Peg-IFN α-2b in combination with ribavirin in anti-human immunodeficiency virus (HIV)-negative patients with
genotype 1 chronic HCV infection.
Methods: The following criteria were to be met for inclusion in the meta-analysis: (a) original data from
randomized and non-randomized clinical trials; (b) study on the efficacy of conventional doses of Peg-IFN α-2a
(180 μg/week) versus Peg-IFN α-2b (1.5 μg/kg of body weight/week), both in combination with ribavirin, in antiviral
therapy-naïve HCV-genotype 1 subjects; (c) at least one of these primary outcomes: Rapid Virological Response
(RVR); Early Complete Virological Response (EVR); End of Treatment Response (ETR); Sustained Virological Response
(SVR); (d) odds ratio estimates of relative risk (RR) and associated 95% confidence intervals (CIs) or at least data
enabling them to be computed; (e) English language; and (f) published as a full paper up to December 2011.
Results: Seven published studies met the inclusion criteria, allowing a meta-analysis on 3,026 patients. Peg-IFN α-2a
and Peg-IFN α-2b showed similar rate of RVR (RR = 1.05; 95% CI = 0.87-1.27, p= 0.62) and SVR (RR = 1.08; 95% CI = 0.99-1.18,
p= 0.098). Peg-IFN α-2a more frequently than Peg-IFN α-2b achieved EVR (RR = 1.11; 95% CI = 1.02-1.21, p= 0.013) and ETR
(RR = 1.22; 95% CI = 1.14-1.31, p< 0.0001).
Conclusion: The standard schedules of Peg-IFN α-2a and Peg-IFN α-2b, both in combination with ribavirin, can be used
indifferently for patients with chronic HCV genotype 1 who are anti- to eliminate HIV-negative and antiviral treatment-naïve.
Keywords: Antiviral therapy in HCV patients, Meta-analysis, Response to anti-HCV therapy, Tolerability of anti-HCV therapy
Background
It is well known that chronic hepatitis C virus (HCV)
infection is responsible for acute hepatitis progressing
to chronicity in about 70% of cases [1]. Half of the
patients with chronic HCV infection require antiviral
treatment with a combined administration of Pegylated
interferon (Peg-IFN) α and ribavirin [2,3]. For patients
with HCV genotype 2 or 3, the treatment is based on a
24-week administration of Peg-IFN given once a week in
combination with a daily oral dose of 800 mg of ribavirin,
whereas for those with HCV genotype 1 or 4, a 48-week
combined treatment with a daily dose of ribavirin be-
tween 13–15 mg/kg is prescribed [4-6]. These treatment
schedules allow a sustained virological response in nearly
80% of patients with HCV genotype 2 or 3 and in 40-45%
of those with HCV genotype 1 [2].
Two formulations of Peg-IFN are on the market, Peg-
IFN α-2a, given at a weekly standard dose of 180 μg, and
Peg-IFN α-2b, given at a dose of 1.5 μg per kg of body
weight. The identification of the best Peg-IFN for chronic
HCV is of minor relevance for patients with genotype 2
or 3 since most of them achieve Sustained Virological
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Response (SVR) with either Peg-IFN formulation [4-6],
whereas patients with HCV genotype 1 show a much
lower rate of SVR [4-6] and, consequently, are at a higher
risk of progression to cirrhosis or hepatocellular carcin-
oma. A difference in the SVR rates between the two Peg-
IFN formulations is of substantial clinical impact for
genotype 1 patients.
Previous studies have compared the effect of the two
formulations, but the results are not conclusive. The
purpose of this meta-analysis was to provide a system-
atic review of all randomized and non-randomized trials
in which the efficacy of Peg-IFN α-2a had been com-
pared with that of Peg-IFN α-2b, both in combination
with ribavirin, in the treatment of patients with genotype
1 chronic HCV. This will provide reliable guidance for
clinical practice and future research, particularly in the
light of the therapy combinations with directly acting
antivirals soon to be released on the market.
Methods
The Quality of Reporting of Meta-analyses guidelines
have been followed throughout the design, implementa-
tion, analysis, and reporting of this meta-analysis [7].
Search strategy
A comprehensive systematic literature search of compu-
terized bibliographic databases including MEDLINE,
EMBASE, LILACS, and the Cochrane Library, from
January 2000 to December 2011, was carried out on the
efficacy of Peg-IFN α-2a versus Peg-IFN α-2b in combin-
ation with ribavirin in patients with genotype 1 chronic
HCV. The search was conducted using both medical sub-
ject heading (MeSH) terminology and more general search
terms. Search terms included, but were not limited to:
Pegylated interferon α-2a, Pegylated interferon α-2b,
HCV infection, HCV-related chronic hepatitis, treatment
of HCV-related chronic hepatitis, Peg-IFNα-2a versus
Peg-IFNα-2b in the treatment of HCV-related chronic
hepatitis. Additionally, reference lists of the selected
papers and the review articles on this topic were manu-
ally scanned to identify any other pertinent studies.
Inclusion and exclusion criteria
The following criteria were necessary for inclusion in
the meta-analysis. The studies had to: (a) present ori-
ginal data from randomized or non-randomized trials;
(b) investigate the efficacy of conventional doses of
Peg-IFN α-2a (180 μg/week) versus Peg-IFN α-2b
(1.5 μg/kg of body weight/week), both in combination
with ribavirin, in antiviral therapy-naïve HCV-genotype
1 subjects; (c) report at least one of the primary out-
comes clearly defined as Rapid Virological Response
(RVR), HCV RNA-negative after 4 weeks of treatment;
Early Complete Virological Response (EVR), HCV RNA-
negative after 12 weeks of treatment; End of Treatment
Response (ETR), HCV RNA-negative on completion of
treatment; and SVR, undetectable HCV RNA 6 months
after therapy completion; (d) report data allowing to cal-
culate the odds ratio estimates of relative risk (RR) for
the effect on different outcomes of therapy with Peg-IFN
α-2a (180 μg/week) versus Peg-IFN α-2b (1.5 μg/kg/
week), both in combination with ribavirin; (e) be writ-
ten in English; and (f ) be published as a full paper up
to December 2011. Studies were excluded if they were
observational or they included patients who had
undergone liver transplantation or were anti-human
immunodeficiency virus (HIV)-positive.
Two investigators (NC and MP) independently
screened title, abstract, and key words of each reference
identified and filled out an inclusion/exclusion form for
all papers. Full copies of included papers were then
retrieved and independently reviewed for eligibility by
the two investigators; contrasting opinions were analyzed
by both investigators and unanimous consensus was
reached after discussion.
Data extraction
Standard information was extracted independently and
in duplicate from each selected study by two investiga-
tors (NC and MP). The data sought included years the
study was performed, baseline patient characteristics,
treatments received, duration of follow-up, types and
numbers of evaluations during the follow-up, risk ratios
(RRs) and standard errors (SEs) of these estimates. If the
latter were not available, they were calculated. Any dis-
agreement between the investigators was resolved as
mentioned above.
Quality assessment
Two investigators (NC and IFA) independently assessed
the quality of the included trials using the Jadad et al. [8]
and the Chalmers et al. [9] methods. The Jadad et al.
scale analyses the criteria related to the randomization
methods (0 to 2 points), double-blinding (0 to 2 points),
and withdrawals (1 point). A numerical score between 0
and 5 was assigned as a measure of study design and
reporting quality, with 0 being the weakest and 5 desig-
nating the strongest. The Chalmers et al. method gives a
handicap to the score of each item according to whether
it has been completely (full score), partially (half score)
or not at all (no score) addressed. If an item in the
protocol was not applicable, the number of possible
points was reduced, thus adapting the scoring system to
different situations. The score for each paper was calcu-
lated as the ratio of the total points assigned divided by
the total number of points considered applicable to that
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study, yielding a range from 0 to the perfect score of 1.
Any disagreement in quality assessment between the
two investigators was resolved as mentioned above.
Statistical analysis
In the primary analysis, all included trials were consid-
ered. The pooled-effects estimates were used to combine
the values from the single studies and were expressed as
RR and 95% confidence interval (CI). RR and CI were
obtained using the Mantel-Haenszel fixed-effects model
[10] if the studies were homogeneous, and the random-
effects models according to the method described by
DerSimonian & Laird [11] in cases with heterogeneity.
Random-effects models incorporate variation both within
and between studies and typically provide wider CIs
when heterogeneity is present. The secondary analysis
was carried out in order to identify any influence of the
design and of the quality of the trials on the findings
obtained. Therefore, a sensitivity analysis was carried
out to identify any influence of the non-randomized
evidence, by grouping only the randomized trials, and
of the quality of the studies, by classifying reports
according to a Jadad et al. score greater than or equal
to the median.
In order to assess statistical heterogeneity, the data
were reanalyzed using both random- and fixed-effects
models. Cochrane’s Q statistics was used to assess
whether differences in the results were comparable
with chance alone. Since this test has low power when
only few studies or studies with a low sample size are
included in a meta-analysis, a p-value < 0.10 was
regarded to indicate significant heterogeneity. The I2
measure was also used [12]. The I2 measure is the per-
centage of total variation across studies that is attribut-
able to heterogeneity rather than chance, where values
approaching zero (0%) indicated no observed hetero-
geneity and larger values increasing heterogeneity. The
random-effects model results were applied in case of
I2 equal or higher than 50%. Heterogeneity was also
assessed through visual inspection of L’Abbé plots.
To assess the potential for publication bias, funnel
plots were constructed for each outcome in which the
log RRs were plotted against their SEs. The Begg rank
correlation test was used to examine the association be-
tween the effects estimates and their variances [13], and
the Egger linear regression test, which regresses z statis-
tics on the reciprocal of the SE for each study, was used
to detect publication bias [14].
All statistical analyses were done with Stata [15].
All the procedures used in the study wherein accord-
ance with the International Guidelines with the standards
on human experimentation of the Ethics committee
of “Azienda Ospedaliera Universitaria of the Second
University of Naples” and with the Helsinki Declar-
ation of 1975 revised in 1983.
Results
Study characteristics
A total of 8,757 citations were identified through elec-
tronic database and manual search using the above-
reported keywords. Of these 8,757 citations, 29 were
considered potentially relevant but only 7 [16-22] met
the inclusion criteria and were included in the meta-
analysis (Figure 1).
Tables 1 and 2 show the characteristics of the studies
included in the meta-analysis. Five of them were pro-
spective randomized trials [16,17,19,20,22], one pro-
spective non-randomized [18], and one retrospective
non-randomized [21]. The studies, published between
2006 and 2010, included from 37 to 2,054 patients. In
all studies, the ribavirin dose was weight-based ranging
from 800 to 1,400 mg and was reduced or discontinued,
respectively, when the hemoglobin level was <10 g/dL or
below 8.5 mg/day. The studies had different approaches
for the reduction of ribavirin: one trial reduced the dose
to 600 mg/day [16], one trial by 200 mg/day (in patients
receiving 800–1,200 mg/die ribavirin) or by 400 mg/day
(in patients receiving 1,400 mg/die) in the Peg-IFN α-2b
arm, and to 600 mg/die in the Peg-IFN α-2a arm [19]; in
two trials it was reduced by 200 mg/die for both regi-
mens [20,22]. All studies reported the data as Intention-
To-Treat analysis, but one study provided data by Per
Protocol analysis [16]. One study was included although
the data on the virological outcome had been presented
for genotypes 1 and 4 [20].
Assessment of quality
Table 3 summarizes the methodological quality assess-
ment of the studies included in the meta-analysis. The
mean overall quality scores of the individual studies
using the Chalmers et al. scale ranged from 0.2 to 0.6
(mean = 0.43), for the Protocol from 0.11 to 0.58
(mean = 0.36) and for the Data Analysis and Presenta-
tion from 0.23 to 0.67 (mean = 0.53). All trials received
full credit for the description of inclusion and rejection
criteria for patient selection, analysis of results of
randomization, and number of patients who withdrew
and the reasons why. Most trials tested the validity of
randomization, reported and discussed side effects of
treatment, indicated the start and stop dates, estimated
variance and/or confidence limits of the endpoints, and
used regression/correlation analysis. In none of the
studies, the observers were masked to the treatment
and results, none presented test statistics and p-value,
or discussed beta error. According to the quality cri-
teria set forth by Jadad et al., none of the studies had
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scores of 5 or 4, three trials scored 3, two scored 1,
and two trials scored 0.
Effects of interventions
Table 4 shows the overall treatment effect of Peg-IFN
α-2a versus Peg-IFN α-2b according to the different
outcomes of interest. The rate of RVR, assessed in 4
studies with 2,729 patients, was similar in the Peg-IFN
α-2a and Peg-IFN α-2b groups. The EVR and ETR
were both evaluated in five studies with a number of
patients respectively of 2,766 and 2,460; the Peg-IFN
α-2a group achieved more frequently than the Peg-IFN
α-2b EVR (RR = 1.11; 95% CI = 1.02-1.21, p = 0.013)
and ETR (RR = 1.22; 95% CI = 1.14-1.31, p < 0.0001).
Six studies assessed the SVR (2,646 patients) and no
significant difference was observed between the Peg-
IFN α-2a and Peg-IFN α-2b groups.
The analysis by subgroups was performed since the
trial conducted by McHutchison et al. [19] reported the
data on ETR and SVR according to the dosage and the
reduction of ribavirin. The analysis including only the
group of patients who received an adequate daily dose of
ribavirin (≥13 mg/kg/day) showed no significant differ-
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Figure 1 Flow chart of the published studies evaluated for inclusion in the meta-analysis.
Table 1 Characteristics of the clinical trials included in the meta-analysis
First Author
[Reference No.]
Country Enrolment period Study* Analysis No. of patients Age, years, mean Gender,% male
Peg-IFN Peg-IFN Peg-IFN
α-2a/α-2b α-2a/α-2b α-2a/α-2b
Yenice [16] Turkey No information RCT, unblinded Per protocol 37/37 48.2 and 50.9^ 35.1/27
50.8 and 50.85§
Di Bisceglie [17] USA No information RCT, unblinded Intention-to-treat 189/191 46.9/48.4 64/71
Escudero [18] Spain May 2001 to
December 2006
Controlled Intention-to-treat 59/58 45.8/45.1 66.1/60.3
McHutchison [19] USA March 2004
to June 2006
RCT# Intention-to-treat 1,035/1,019 47.6/47.5 59.2/60.2
Ascione [20] Italy March 2004 to
December 2006
RCT, unblinded Intention-to-treat 93/93 51.3/48.9° 50.6/58.8°
Lee [21] Korea May 2004 to
February 2009
Controlled Intention-to-treat 21/16 53.4/53.6° 64.6/55.3°
Rumi [22] Italy September 2003 to
June 2007
RCT, unblinded Intention-to-treat 91/87 51.6/52.8° 60.4/54.8
* RCT randomized controlled trial; # Random double-blinded with regard to the dose of Peg-IFN alfa-2b; ^ Male; § Female; ° All genotypes.
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Table 2 Outcomes in the studies included in the meta-analysis
First Author
[Reference No.]
Outcomes, n° (%) of patients in Peg-IFN α-2a/α-2b group
RVR EVR ETR SVR Discontinuation of therapy for
adverse events in patients with
genotype 1 all genotypes
Peg-IFN reduction for adverse
events in patients with
all genotypes
Yenice [16] # 28(75.7)/27(73) 18(48.6)/13(35.1) 3 (7.5)/3 (7.5) 3 (7.5)/3 (7.5)
Di Bisceglie [17] § 14(7.4)/22(11.5) 74(39.1)/84(43.9)
Escudero [18] † 15(25.4)/10(17.2) 33(55.9)/29(50) 12(20.3)/7(12.1) 30(50.8)/27(46.6) 12(13.1)/10(10.8) 8(8.7)/7(7.6)
McHutchison [19] $ 123(11.9)/116(11.4) 466(45)/407(39.9) 667(64.4)/542(53.2) 423(40.9)/406(39.8) 135(13)/129(12.6) 135(13)/129(12.6) 264(25.5)/254(24.9)
Ascione [20] § 51(54.8)/37(39.8) 3 (3.2)/13 (14) 4(2.5)/22(13.7)
Lee [21] ^ 16(76.2)/12(75) 16(76.2)/13(81.3) 8(38)/10(62.5) 8(10.1)/5(10.6)
Rumi [22] ç 34(37)/26(30) 60(66)/40(46) 59(65)/38(44) 44(48)/28(32) 16(7.5)/17(7.7) 22(10.3)/14(6.3)
Dosage of ribavirin
# 40–64 kg of weight: 800 mg/day; 65–85 kg: 1,000 mg/day; >85 kg: 1,200 mg/day.
§ <75 kg of weight: 1,000 mg/day; ≥75 kg: 1,200 mg/day.
† ≤65 kg of weight: 800 mg/day; 65–75 kg: 1,000 mg/day; >75 kg: 1,200 mg/day.
$ In the Peg-IFN α-2b arm: 40–65 kg of weight: 800 mg/day; >65-85 kg: 1,000 mg/day; >85-105 kg: 1,200 mg/day; >105-125 kg: 1,400 mg/day. In the Peg-IFN α-2a arm: <75 kg: 1,000 mg/day; ≥75 kg: 1,200 mg/day.
^ In the Peg-IFN α-2a arm: <75 kg of weight: 1,000 mg/day; ≥75 kg: 1,200 mg/day. In the Peg-IFN α-2b arm: <65 kg: 800 mg/day; 65–85 kg: 1,000 mg; >85 kg: 1,200 mg.




















achievement of SVR. Moreover, in the analysis including
only the patients who did not receive a reduction in the
dosage of ribavirin during treatment, Peg-IFN α-2a had
a significantly better effect than Peg-IFN α-2b on ETR
(RR = 1.29; 95% CI = 1.18-1.41, p < 0.0001) and SVR
(RR = 1.13; 95% CI = 1.01-1.26, p = 0.04).
The sensitivity analyses, performed by excluding the
trials deemed to be of poor methodological quality and
by excluding the non-randomized trials, revealed that
the overall findings regarding all outcomes were not
affected and no significant differences were observed in
the pooled-effect estimates, thus confirming the robust-
ness of the results of the meta-analysis. No homogeneity
test showed statistically significant heterogeneity.
Some of the studies described the adverse events (AE)
leading to the discontinuation of antiviral treatment or a
reduction in the Peg-IFN dose. Three studies including
2,320 patients reported the discontinuation of treatment,
but no significant difference was observed between the
Peg-IFN α-2a and Peg-IFN α-2b groups (RR = 0.96;
95% CI = 0.77-1.19, p = 0.7; test for heterogeneity Q = 5.61,
p = 0.06; I2 = 64.4%) regarding discontinuation. It was not
possible to evaluate the rate of AE leading to a reduction
in the Peg-IFN dose, since only one trial reported these
data [19]. The rate of AE leading to discontinuation of
antiviral therapy or to a reduction in Peg-IFN dose was
also evaluated in the included studies considering patients
with genotype 1 and non-1. The AE leading to the dis-
continuation of Peg-IFN were reported in 6 studies
(3,194 patients) and those leading to Peg-IFN reduction in
3 (2,668 patients); no significant differences were found
between Peg-IFN α-2a and Peg-IFN α-2b regarding the
occurrence of AE leading to discontinuation (RR = 0.93;
95% CI = 0.77-1.13, p = 0.48; test for heterogeneity
Table 4 Summary of meta-analysis results in the achievement of the virological outcome by Pegylated interferon α-2a
and α-2b plus ribavirin in patients with genotype 1 chronic hepatitis C






Rapid Virological Response 4 [17-19,22] 1,374/1,355 186(13.5)/174(12.8) 1.05 0.87–1.27 0.62 3.8;0.28;21.1
Early Virological Response 5[17-19,21,22] 1,395/1,371 649(46.5)/572(38.4) 1.12 1.03–1.22 0.011 7.58;0.14;42.8
End of Treatment Response 5[16,18,19,21,22] 1,243/1,217 782(62.9)/627(51.5) 1.22 1.14–1.31 <0.0001 7.6;0.11;47.3
5*[16,18,19,21,22] 921/879 544(59)/403(45.8) 1.29 1.18–1.41 <0.0001 8.37;0.08;52.1
Sustained Virological Response 6[16,18-22] 1,336/1,310 574(43)/521(39.8) 1.08 0.99–1.18 0.098 9.97;0.08;49.8
6**[16,18-22] 1,058/732 473(44.7)/306(41.8) 1.08 0.97–1.20 0.19 10.9;0.053;54.2
6*[16,18-22] 1,014/972 406(40)/346(35.5) 1.13 1.01–1.26 0.04 8.59;0.13;41.8
* In McHutchison’s study [19] only patients without ribavirin reduction were included.
** In McHutchison’s study [19] only patients with adequate ribavirin dosage (≥13 mg/kg/die) were included.




1 2 3 4 5 6 7 8 9 10 11 Protocol 12 13 14 15 16 17 18 19 20 21 22 Data
analysis
Overall 1 2 3 Overall
Yenice [16] 1 0 1 0 0 0 0 0 0 1 0 0.17 0 1 0 0 0 0 0 1 0 0 0 0.23 0.2 1 0 0 1
Di Bisceglie [17] 1 0 1 0 0 0 0 1 1 1 n.
a.
0.35 0 1 0 0 1 0 0 1 0 1 0 0.44 0.39 1 0 0 1
Escudero [18] 1 0 1 0 0 0 0 0 0 0 0 0.11 1 1 0 0 1 1 0 1 0 1 0 0.61 0.31 0 0 0 0
McHutchison
[19]
1 1 1 1 0 0 0 1 1 1 0 0.58 1 1 0 0 1 1 0 1 0 1 0 0.61 0.6 2 0 1 3
Ascione [20] 1 1 1 1 0 0 0 1 1 1 0 0.54 1 1 0 n.
a.
1 1 0 1 0 1 0 0.67 0.59 2 0 1 3
Lee [21] 1 0 1 0 0 0 1 0 0 1 0 0.15 1 1 0 0 0 1 0 1 0 1 0 0.54 0.37 0 0 0 0
Rumi [22] 1 1 1 1 0 0 0 1 1 1 0 0.54 1 1 0 n.
a.
1 1 0 1 0 1 0 0.67 0.59 2 0 1 3
For the Chalmers et al. method: 0 is “Non adequate”, 1 is “Adequate” for the following items: 1 Selection description; 2 Number and reasons for eligible patients
not included in the study; 3 Regimen definition; 4 Blinding of Randomization; 5 Blinding of Patients to therapy; 6 Blinding of Physicians/observers to therapy; 7
Blinding of Physicians/observers to ongoing results; 8 Regimen definition; 9 Statistical estimate of sample size; 10 Testing randomization; 11 Testing compliance;
12 Dates of study; 13 Results of prerandomization; 14 Both test statistics and P value given; 15 Post beta estimate; 16 Confidence intervals given; 17 Regression/
correlation; 18 Statistical analysis; 19 Number and reasons for patients withdrawn after randomization; 20 Withdrawals handled in several ways; 21 Side effects
discussion; 22 Subgroups retrospective analysis. For the Jadad et al. the points are assigned for the following items: 1 Randomization; 2 Double-blinding; 3
Withdrawals and drop-out.
n.a. not applicable.
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Q= 10.65, p = 0.06; I2 = 53.1%) or to reduction in the
Peg-IFN dosage (RR = 1.06; 95% CI = 0.92-1.22, p = 0.45;
test for heterogeneity Q = 1.92, p = 0.38; I2 = 0%).
Visual analysis of L’Abbé plots for the efficacy rate in
the Peg-IFN α-2a and Peg-IFN α-2b groups of different
outcomes gave no evidence of heterogeneity in the stud-
ies included in the meta-analysis (Figure 2).
A funnel plot of the effect size versus standard error
from each study was generated to evaluate the presence
of a potential publication bias with regard to the meta-
analysis performed. Visual analysis of the funnel plots
at all stages of the review and the rank correlation or
regression testing gave no evidence of publication bias
in the studies included in the meta-analysis. Neither
Egger’s test (p > 0.20) nor Begg’s test (p > 0.20) was sig-
nificant and gave no evidence for publication bias
(Figure 3).
Discussion and conclusion
This meta-analysis summarized the results of studies
comparing Peg-IFN α-2a with Peg-IFN α-2b adminis-
tered weekly subcutaneously in combination with a daily
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Figure 2 L’Abbé plot for efficacy rate in Peg-IFN α-2a and Peg-IFN α-2b groups on the different outcomes of interest.
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patients with genotype 1 chronic HCV. The data show
that there is no difference between the two treatments
in the achievement of RVR and SVR; the higher rates of
EVR and ETR in the patients treated with Peg-IFN α-2a
are clearly of lesser clinical impact. The datum on SVR
may be considered the most important result from this
meta-analysis. In fact, it is well known that SVR is the
most reliable indicator of HCV eradication; a follow-up
study on more than 1,300 patients with SVR achieved
with Peg-IFN α, alone or in combination with ribavirin,
found that the recurrence of HCV RNA was rarely
recorded after a mean of 3.9 years [23].
As already stated, some of the previously conducted
studies showed no difference between the two treat-
ments in the rate of SVR in therapy-naïve patients with
HCV genotype 1 [16,18,19]; in other studies, SVR was
observed more frequently with Peg-IFN α-2a [20,22]; fi-
nally, in one trial the patients treated with Peg-IFN α-2b
achieved SVR more frequently, although this difference
was not statistically significant [21]. It is well known that
a meta-analysis allows an unbiased pooling of available
evidence regarding the efficacy of any given intervention,
but two other meta-analyses [24,25] included different
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Figure 3 Funnel plot of the risk ratios vs. the reciprocal of their standard errors of trials evaluating the efficacy of Peg-IFN α-2a versus
Peg-IFN α-2b on the different outcomes of interest.
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patients with different clinical characteristics. In both
meta-analyses, the researchers pooled the results from
randomized trials on patients with different HCV geno-
types, full papers and abstracts, thus reducing the quality
and reliability of the results. The meta-analysis by Awad
and colleagues’ included anti-HIV-positive patients, non-
responders to previous treatment, and those treated with
sub-optimal doses of Peg-IFN α-2b, and found that SVR
was more frequently achieved in patients with genotype
1 or 4 treated with Peg-IFN α-2a plus ribavirin than in
those receiving Peg-IFN α-2b plus ribavirin [24]. More-
over, it should be pointed out that the studies consider-
ing subgroups of patients receiving a sub-optimal or
insufficient dosage of one or both drugs were not
included in our meta-analysis. Also excluded were the
studies that included patients with HCV infection who
were non-responders to previous antiviral treatment and
those with HCV/HIV coinfection, who in previous inves-
tigations showed a much lower SVR rate than therapy-
naïve and anti-HIV-negative patients [2,26-28]. The
meta-analysis by Zhao and colleagues pooled the results
from trials on patients with genotype 1 and 4 and on
those with genotype 2 and 3; they reported that SVR
was more frequently associated to the use of Peg-IFN
α-2a than Peg-IFN α-2b in patients with HCV geno-
type 2 or 3, whereas the overall effect in the subset of
patients with genotype 1 or 4 was not significant [25].
A low dose of ribavirin and/or its reduction during
treatment were associated to a high rate of relapse after
antiviral treatment and, thus, to a low rate of SVR
[29,30]. Among the trials enrolled in our meta-analysis
McHutchison’s study reports the data on SVR according
to the dosage and to the reduction of ribavirin during
treatment, allowing a sub-analysis of the relative sub-
groups [19]. Considering only the patients receiving an
adequate daily dose of ribavirin (≥13 mg/kg/die) in
McHutchison’s trial, no difference in the achievement of
SVR was found between the Peg-IFN α-2a and Peg-IFN
α-2b schedules. Considering only the patients with no
reduction of ribavirin during treatment, Peg-IFN α-2a
compared with Peg-IFN α-2b more frequently achieved
SVR, but the data of this sub-analysis are strongly
impaired by the lack of information on the ribavirin dose
prescribed for this subset of patients.
The present meta-analysis also evaluated the rate of
adverse events leading to the discontinuation of treat-
ment or to a reduction of the Peg-IFN dose. However,
since these data for patients with HCV genotype 1 were
reported only in a few trials, the rate of adverse events
in the meta-analysis includes all the studies considering
patients with genotype 1 or non-1. The treatment sche-
dules were frequently burdened by adverse events that
had a substantial clinical impact, with approximately
10% of patients discontinuing the treatment schedules
and 6-25% receiving a reduced Peg-IFN dose because
of such events. It is important to underline that the
data show that Peg-IFN α-2a and Peg-IFN α-2b had
similar frequencies of adverse events leading to treat-
ment discontinuation or drug dosage reduction, but it
should be noted that the adverse effects of treatment
were inconsistently reported in the papers included in
the meta-analysis. Although this was not a specific ob-
jective, these aspects may introduce a bias and are likely
to contribute to the underestimation of the true burden
of effect. This meta-analysis shows that clearly defined,
standardized clinical endpoints, particularly for the ad-
verse events, would greatly enhance the interpretation
of trial evidence.
The overall quality of each trial included in the meta-
analysis was particularly disappointing. In none of the
studies were the observers masked to treatment and to
the results, and many studies did not describe the
randomization procedures in detail. Although the poor
quality of the studies can affect the results and may
undermine confidence in the conclusions drawn, it
should be pointed out that the magnitude and direction
of the results did not change in the sensitivity analysis
when trials with a low quality score were excluded. Simi-
larly, the results did not change significantly when the
data from the non-randomized trials were removed.
Thus, the sensitivity analysis strengthens the validity of
the overall conclusion that the efficacy of Peg-IFN α-2a
was similar to that of Peg-IFN α-2b. The finding that the
results of the sensitivity analysis did not modify those of
the meta-analysis may at least be explained in part by the
fact that the McHutchison trial [19] accounted for more
than two-thirds of all patients included.
The potential limitations of this meta-analysis are those
of any meta-analytic venture and should be acknowl-
edged. First, the possibility of a publication bias needs to
be borne in mind, particularly in a meta-analysis based
only on published studies, because “positive” studies
are more likely to be submitted and published than
“negative” studies, and so it is possible that other small
“negative” studies have been conducted and their results
never published. However, because this is a relatively
new treatment, it is improbable that other “negative”
studies exist. The literature search was conducted by
searching multiple electronic databases, the reference
lists of the retrieved manuscripts and reviews of experts
in this field and was limited to articles published in the
English language. We purposefully did not contact the
authors of the articles included in this meta-analysis, be-
cause we wished to assess the evidence as it stands in the
public domain. Finally, the need to combine results from
randomized and non-randomized studies constitutes a
potential limitation. However, the results of the sensitiv-
ity analysis did not show any difference in the efficacy of
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the treatment in relation to the type and quality between
the randomized and non-randomized studies, and im-
portantly, the absence of statistical heterogeneity or pub-
lication bias suggests that the results are robust. Despite
its limitations, this meta-analysis provides the most com-
prehensive and updated summary of the epidemiological
evidence to date on the efficacy of Peg-IFN α-2a com-
pared to Peg-IFN α-2b, both in combination with riba-
virin, in the treatment of patients with HCV genotype 1
chronic HCV.
In conclusion, this meta-analysis found a similar SVR
rate between the standard schedule of Peg-IFN α-2a and
Peg-IFN α-2b, both in combination with ribavirin, and
therefore both treatments can be used indifferently for
patients with genotype 1 chronic hepatitis C who are
anti-HIV-negative and naïve to antiviral treatment.
Abbreviations
ETR: End of Treatment Response; EVR: Early Complete Virological Response;
Peg-IFN: Pegylated interferon; RVR: Rapid Virological Response; SVR: Sustained
Virological Response; HCV: Hepatitis C virus; HIV: Human immunodeficiency
virus; RRs: Risk ratios; SEs: Standard errors; CI: Confidence interval; AE: Adverse
events.
Competing interests
The authors declare that they have no competing interest.
Authors’ contributions
NC was responsible for the conception and design of the study, performed
the data extraction, assessed the quality, interpreted the data and wrote the
manuscript. MP participated in the conception of the study, performed the
data extraction and interpreted the data. CS performed the literature search
and interpreted the data. GT performed the literature search and interpreted
the data. ES critically revised the manuscript for important intellectual
contribution. IFA was responsible for the conception and design of the
study, assessed the quality of the studies, analysed the data and wrote the
manuscript. All authors read and approved the final manuscript.
Author details
1Department of Public Medicine, Section of Infectious Diseases, Second
University of Naples, Naples, Italy. 2Department of Experimental Medicine,
Section of Hygiene, Second University of Naples, Naples, Italy. 3Division of
Infectious Diseases, Azienda Ospedaliera Sant’Anna e San Sebastiano di
Caserta, Caserta, Italy. 4Department of Clinical and Experimental Medicine
and Surgery, “F. Magrassi e A. Lanzara”, Second University of Naples, Naples,
Italy.
Received: 5 April 2012 Accepted: 10 December 2012
Published: 18 December 2012
References
1. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP: The contributions
of hepatitis B virus and hepatitis C virus infections to cirrhosis and
primary liver cancer worldwide. J Hepatol 2006, 45:529–538.
2. Ghany MG, Strader DB, Thomas DL, Seef IL: Diagnosis, management and
treatment of hepatitis C: an update. Hepatology 2009, 49:1335–1374.
3. Practice guidelines for the treatment of hepatitis C: Practice guidelines for
the treatment of hepatitis C: Recommendations from an AISF/SIMIT/
SIMAST Expert Opinion Meeting. Dig Liv Dis 2010, 42:81–91.
4. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R,
Goodman ZD, Koury K, Ling M, Albrecht JK: Peginterferon alfa-2b plus
ribavirin compared with interferon alfa-2b plus ribavirin for initial
treatment of chronic hepatitis C: a randomised trial. Lancet 2001,
358:958–965.
5. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr,
Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J,
Yu J: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus
infection. N Engl J Med 2002, 347:975–982.
6. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P,
Ramadori G, Bodenheimer H Jr, Bernstein D, Rizzetto M, Zeuzem S, Pockros
PJ, Lin A, Ackrill AM: PEGASYS International Study Group Peginterferon-
alpha2a and ribavirin combination therapy in chronic hepatitis C: a
randomized study of treatment duration and ribavirin dose. Ann Intern
Med 2004, 140:346–355.
7. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF: Improving the
quality of reports of meta-analyses of randomised controlled trials: the
QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 1999,
354:1896–1900.
8. Jadad AR, Moore RA, Carrol D, Jenkinson C, Reynolds DJM, Gavalghon DJ:
Assessing the quality of reports of randomized clinical trials. Is blinding
necessary? Control Clin Trials 1996, 17:1–12.
9. Chalmers TC, Smith H Jr, Blackburn B, Silverman B, Schroeder B, Reitman D:
A method for assessing the quality of a randomized control trial. Control
Clin Trials 1981, 2:31–49.
10. Mantel N, Haenszel W: Statistical aspects of the analysis of data from
retrospective studies of disease. J Natl Cancer Inst 1959, 22:719–748.
11. Der Simonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials
1986, 7:177–188.
12. Higgins JP, Thompson SG: Quantifying heterogeneity in a meta-analysis.
Stat Med 2002, 21:1539–1558.
13. Begg CB, Mazumdar M: Operating characteristics of a rank correlation
test for publication bias. Biometrics 1994, 50:1088–1099.
14. Egger M, Davey Smith G, Schneider M, Minder C: Bias in meta-analysis
detected by a simple, graphical test. BMJ 1997, 315:629–634.
15. Corporation S: Stata Statistical Software: Release 10. TX, USA: College Station;
2010.
16. Yenice N, Mehtap O, Gumrah M, Arican N: The efficacy of pegylated
interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients.
Turk J Gastroenterol 2006, 17:94–98.
17. Di Bisceglie AM, Ghalib RH, Hamzeh FM, Rustgi VK: Early virologic response
after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b
plus ribavirin treatment in patients with chronic hepatitis C. J Vir Hep
2007, 14:721–729.
18. Escudero A, Rodríguez F, Serra MA, Del Olmo JA, Montes F, Rodrigo JM:
Pegylated alpha-interferon-2a plus ribavirin compared with pegylated
alpha-interferon-2b plus ribavirin for initial treatment of chronic
hepatitis C virus: prospective, non-randomized study. J Gastroenterol
Hepatol 2008, 23:861–866.
19. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J,
Nyberg LM, Lee WM, Ghalib RH, Schiff ER, Galati JS, Bacon BR, Davis MN,
Mukhopadhyay P, Koury K, Noviello S, Pedicone LD, Brass CA, Albrecht JK,
Sulkowski MS: IDEAL Study Team Peginterferon alfa-2b or alfa-2a with
ribavirin for treatment of hepatitis C infection. N Engl J Med 2009,
361:580–593.
20. Ascione A, De Luca M, Tartaglione MT, Lampasi F, Di Costanzo GG, Lanza
AG, Picciotto FP, Marino-Marsilia G, Fontanella L, Leandro G: Peginterferon
alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus
ribavirin for treating chronic hepatitis C virus infection. Gastroenterology
2010, 138:116–122.
21. Lee S, Kim IH, Kim SH, Kim SW, Lee SO, Lee ST, Kim DG, Lee CS, Choi CS,
Cho EY, Kim HC: Efficacy and tolerability of pegylated interferon-alpha2a
plus ribavirin versus pegylated interferon-alpha2b plus ribavirin in
treatment-naive chronic hepatitis C patients. Intervirology 2010, 53:146–153.
22. Rumi MG, Aghemo A, Prati GM, D'Ambrosio R, Donato MF, Soffredini R, Del
Ninno E, Russo A, Colombo M: Randomized study of peginterferon-
alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic
hepatitis C. Gastroenterology 2010, 138:108–115.
23. Swain MG, Lai MY, Shiffman ML, Cooksley WG, Zeuzem S, Abergel A, Pessôa
MG, Lin A, Tietz A, Connell EV, Diago M: A Sustained Virologic Response is
durable in patients with chronic hepatitis C treated with peginterferon
alfa-2a and ribavirin. Gastroenterology 2010, 139:1593–1601.
24. Awad T, Thorlund K, Hauser G, Stimac D, Mabrouk M, Gluud C:
Peginterferon alpha-2a is associated with higher sustained virological
response than peginterferon alfa-2b in chronic hepatitis C: systematic
review of randomized trials. Hepatology 2010, 51:1176–1184.
25. Zhao S, Liu E, Chen P, Cheng D, Lu S, Yu Q, Wang Y, Wei K, Yang P: A
comparison of peginterferon α-2a and α-2b for treatment-naive patients
Coppola et al. BMC Infectious Diseases 2012, 12:357 Page 10 of 11
http://www.biomedcentral.com/1471-2334/12/357
with chronic hepatitis C virus: a meta-analysis of randomized trials. Clin
Ther 2010, 32:1565–1577.
26. Taliani G, Gemignani G, Ferrari C, Aceti A, Bartolozzi D, Blanc PL, Capanni M,
Esperti F, Forte P, Guadagnino V, Mari T, Marino N, Milani S, Pasquazzi C,
Rosina F, Tacconi D, Toti M, Zignego AL, Messerini L, Stroffolini T: Pegylated
interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin
nonresponder patients. Gastroenterology 2006, 130:1098–1106.
27. Torriani FJ, Rodriguez-Torris M, Rockstroh JK, Lissen E, Gonzalez-García J,
Lazzarin A, Carosi G, Sasadeusz J, Katlama C, Montaner J, Sette H Jr, Passe S,
De Pamphilis J, Duff F, Schrenk UM, Dieterich DT: Peginterferon alfa-2a
plus ribavirin for chronic hepatitis C virus infection in HIV infected
patients. N Engl J Med 2004, 351:438–450.
28. Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, Koziel
MJ, Bhan AK, Alston B, Colquhoun D, Nevin T, Harb G, van der Horst C:
Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin
for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004,
351:451–459.
29. Hiramatsu N, Oze T, Yakushijin T, Inoue Y, Igura T, Mochizukiet K, Imanaka K,
Kaneko A, Oshita M, Hagiwara H, Mita E, Nagase T, Ito T, Inui Y, Hijioka T,
Katayama K, Tamura S, Yoshihara H, Imai Y, Kato M, Yoshida Y, Tatsumi T,
Ohkawa K, Kiso S, Kanto T, Kasahara A, Takehara T, Hayashi N: Ribavirin
dose reduction raises relapse rate dose-dependently in genotype 1
patients with hepatitis C responding to pegylated interferon alpha-2b
plus ribavirin. J Vir Hep 2009, 16:586–594.
30. Jacobson IM, Brown RS, Freilich B, Afdhal N, Kwo PY, Santoro Y, Hargrave T,
Kwo PY, Lambiase L, Galler GW, Araya V, Freilich B, Harvey J, Griffel LH, Brass
CA: Peginterferon alfa-2b and weight-based or flat-dose ribavirin in
chronic Hepatitis C patients: a randomized trial. Hepatology 2007,
46:971–981.
doi:10.1186/1471-2334-12-357
Cite this article as: Coppola et al.: Efficacy of pegylated interferon α-2a
and α-2b in patients with genotype 1 chronic hepatitis C: a meta-
analysis. BMC Infectious Diseases 2012 12:357.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Coppola et al. BMC Infectious Diseases 2012, 12:357 Page 11 of 11
http://www.biomedcentral.com/1471-2334/12/357
